The α(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120  by Balzarini, Jan
FEBS Letters 581 (2007) 2060–2064The a(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin
potentiates the antiviral activity of carbohydrate-binding agents
against wild-type and mutant HIV-1 strains containing
glycan deletions in gp120
Jan Balzarini*
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium
Received 13 February 2007; revised 6 April 2007; accepted 12 April 2007
Available online 25 April 2007
Edited by Hans-Dieter KlenkAbstract Exposure of carbohydrate-binding agents (CBAs)
(i.e. the mannose-speciﬁc plant lectins Hippeastrum hybrid
agglutinin and Galanthus nivalis agglutinin) to HIV-1 progres-
sively select for mutant HIV-1 strains that contain N-glycan
deletions in their envelope gp120. This results in resistance of
the mutant virus strains to the CBAs. Exposure of such mutant
virus strains to the a(1,2)-mannosidase I inhibitor 1-deoxyman-
nojirimycin (DMJ) results in an enhanced suppression of mutant
virus-induced cytopathicity in CEM cell cultures. Moreover,
when combined with CBAs at concentrations that showed poor
if any suppression of mutant virus replication as single drugs, a
synergistic antiviral activity of DMJ was observed. These obser-
vations argue for a combined exposure of CBAs and glycosyla-
tion inhibitors such as DMJ to HIV to aﬀord a more
pronounced suppression of virus replication, prior to, or during,
CBA resistance development.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The majority of enveloped viruses contains multiple glycans
on their envelope proteins. In some cases (i.e. human immuno-
deﬁciency virus, HIV) [1], hepatitis C virus (HCV) [2], coro-
naviruses (CoV) [3], inﬂuenza virus (INF) [4]), the envelope
is extensively glycosylated. The gp120 envelope of HIV is
among the most heavily glycosylated proteins known [5]. Pro-
tein glycosylation may serve multiple functions, including
proper folding of the nascent peptide, avoiding peptide precip-
itation due to the presence of lipophylic amino acid domains in
the protein, protection against breakdown by proteases,
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eties. Pucases, escape of immune surveillance [6]. After the glycan
building block (GlcNAc)2Man9Glc3 has been added to aspar-
agines of the native peptide that are part of a N-glycosylation
motif (NXS/T), the N-glycans are processed by a-glucosidases
to remove the terminal three glucoses in the endoplasmatic
reticulum (ER). Then, ER and Golgi class I a1,2-mannosidases
speciﬁcally hydrolyze a1,2-mannose residues, and catalyse the
trimming of the high-mannose chains involving four a1,2-
linked mannose residues, and this process generates Man5Glc-
NAc2. Subsequent action of GlcNAc transferase I initiates
complex chain formation and yields the substrate for Golgi
a-mannosidase II which trims the terminal a1,3- and a1,6-
mannose residues [7]. Further processing events in the Golgi
apparatus eventually lead to glycans that consist of a wide
variety of carbohydrates and combinations thereof [7–10].
Since mammalian viruses use the host cell glycosylation
machinery for glycan synthesis and modiﬁcation of the glycans
that need to be incorporated in their envelope glycoproteins, it
has been suggested that it is possible to target the viral enve-
lope glycoproteins by inhibiting certain host-cell glucosidases
at low levels that do not aﬀect host-cell viability [5]. The
altered glycan structures on the viral envelope proteins may
then result in decreased viral infectivity (ﬁtness), virus assem-
bly and/or virus particle release [5]. HIV infectivity has indeed
shown to be suppressed in cell culture when the virus was
propagated in the presence of the a-glucosidase inhibitor
NB-DNJ [11]. The latter drug has been evaluated in phase II
clinical trials as an anti-HIV therapeutic [12]. For hepatitis B
virus (HBV), it was demonstrated that NN-DNJ (and also to
a minor extent NB-DNJ) disrupted the proper folding and eﬃ-
cient release of the viral envelope molecules. It was shown that
NB-DNJ could reduce virus levels in a dose-dependent manner
[13]. Since the E1 and E2 transmembrane glycoproteins of
HCV are important for host cell entry [14], and since proper
folding is calnexin-dependent [15], glucosidase inhibitors may
also be expected to aﬀect HCV entry and infectivity.
Recently, we have shown that carbohydrate-binding agents
(CBA) are able to force HIV-1 to delete part of the glycans
on its gp120 envelope in an attempt to escape drug pressure
[16–19]. Such mutant virus strains display diﬀerent degrees of
phenotypic (in)sensitivity to the CBA’s antiviral activity
depending the number and the nature of the glycans that were
deleted in gp120. In this study, we wanted to investigate
whether the concomitant combination of CBAs and the
glycosylation inhibitor 1-deoxymannojirimycin (DMJ) againstblished by Elsevier B.V. All rights reserved.
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1 strains could aﬀord a superior antiviral activity than when
added as single drugs. DMJ was used because it selectively
inhibits a1,2-mannosidase I resulting in the accumulation of
high-mannose glycans on the viral envelope glycoprotein. We
found a signiﬁcantly increased sensitivity of the mutant virus
strains to the inhibition by DMJ, and a marked potentiation
of the antiviral eﬃcacy of CBAs when co-administered with
DMJ, both for wild-type and mutant virus strains.2. Materials and methods
2.1. Test compounds
The mannose-speciﬁc plant lectins from Galanthus nivalis (GNA)
and Hippeastrum hybrid (HHA) were derived and puriﬁed from these
plants, as described before [20,21]. DMJ was obtained from Sigma–Al-
drich (St. Louis, MO) and from Calbiochem (VWR International,
Haasrode, Belgium).
2.2. Cells
Human T-lymphocytic CEM cells were obtained from the American
Type Culture Collection (Manassas, VA) and cultivated in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS) (BioWit-
taker Europe, Verviers, Belgium), 2 mM L-glutamine and 0.075 M
NaHCO3.
2.3. Viruses
HIV-1(IIIB) was provided by Dr. R.C. Gallo and Dr. M. Popovic (at
that time at the National Cancer Institute (NCI), National Institutes of
Health (NIH), Bethesda, MD). The mutant virus strains were obtained
and characterized as described before [22].2.4. Antiretrovirus assays
The methodology of the anti-HIV assays has been described previ-
ously [16,17]. Brieﬂy, CEM cells (4.5 · 105 cells per ml) were suspended
in fresh culture medium and infected with HIV-1 at 100 CCID50 per ml
of cell suspension. Then, 100 ll of the infected cell suspension were
transferred to microplate wells, mixed with 100 ll of the appropriate
dilutions of the test compounds, and further incubated at 37 C. After
4–5 days, giant cell formation was recorded microscopically in the
CEM cell cultures. The 50% eﬀective concentration (EC50) corresponds
to the compound concentrations required to prevent syncytium forma-
tion by 50% in the virus-infected CEM cell cultures. In the drug com-
bination experiments, DMJ was added to the cell cultures prior to the
addition of the CBA and virus infection of the drug-exposed cells. The
proper control experiments in which only one of the drugs or none of
the drugs were present, were carried out under similar experimentalTable 1
Glycan deletions present in the gp120 envelope of mutant HIV-1 strainsa
Position of the N-glycan
amino acid deletion














aGlycan deletions at the N-glycosylation sites in gp120 (indicated as +) as
(glycan containing) wild-type sequence. The ‘‘±’’ notation refers to the pres
isolate.
bC: complex-type glycan, M: high-mannose type glycan [19].conditions. Data of representative experiment were shown in the ﬁg-
ures.3. Results
3.1. Antiviral eﬀect of the glycosylation inhibitor DMJ and the
CBAs HHA and GNA against wild-type and mutant HIV-1
strains
The antiviral activity of the a(1,2)-mannosidase I inhibitor
DMJ and the mannose-speciﬁc plant lectins HHA and GNA
was investigated against wild-type HIV-1(IIIB) and three mu-
tant HIV-1(IIIB) strains that contain a variety of 7–8 glycan
deletions in their envelope gp120 (Table 1). DMJ did not sup-
press HIV-1(IIIB)-induced cytopathicity in CEM cell cultures
at a concentration as high as 500 lM. However, when DMJ
was evaluated for its antiviral activity against the mutant virus
strains, it had gained, as such, measurable antiviral eﬃcacy.
DMJ was inhibitory at an EC50 that ranged between 90 and
155 lM against the mutant virus strains. Thus, the cytopathic
activity of the mutant virus strains was invariably suppressed
by DMJ (Table 2). In contrast, the CBAs HHA and GNA that
showed EC50 values as low as 0.28 and 0.16 lg/ml against wild-
type HIV-1(IIIB), respectively, markedly lost their pronounced
suppressive activity against the three mutant virus strains
(EC50: 58–500 lg/ml) (Table 2). Thus, the deleted glycans in
HIV-1 gp120 clearly compromised the antiviral activity of
the CBAs.
3.2. Antiviral eﬀect of CBAs in combination with DMJ against
wild-type HIV-1 in CEM cell cultures
The eﬀect of 250 and 100 lMDMJ on the inhibitory activity
of the CBAs HHA and GNA against wild-type HIV-1 replica-
tion in CEM cell cultures was investigated (Fig. 1). As already
mentioned above, DMJ was not inhibitory against HIV-1-in-
duced cytopathicity at the concentrations used (250 and
100 lM). In contrast, HHA (Fig. 1A) and GNA (Fig. 1B) as
single drugs completely prevented HIV-1-induced CPE in the
CEM cell cultures at concentrations as low as 0.8 lg/ml. At
0.16 lg/ml, HHA and GNA were 25% and 50% inhibitory,
respectively. At 0.032 lg/ml, no residual inhibitory eﬀect of
the CBAs was observed. Interestingly, co-administration of














determined in ref. 22. The ‘‘’’ notation refers to the presence of the
ence of a mixture of the wild-type and mutated sequence in the virus
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Fig. 1. Eﬀect of 1-deoxymannojirimycin on the antiviral eﬀect of HHA
and GNA against HIV-1-infected CEM cell cultures.
Table 2
Antiviral activity of 1-deoxymannojirimycin (DMJ) and the CBAs HHA and GNA against wild-type and mutant HIV-1 strains
Compound EC50 (lg/ml)
a
HIV-1/WT HIV-1/GNA500(CS)b HIV-1/HHA500(CS)b HIV-1/HHA500(SN)b
DMJc >500 90 ± 60 155 ± 141 103 ± 80
HHA 0.31 ± 0.13 67 ± 31 125 ± 35 127 ± 59
GNA 0.45 ± 0.26 103 ± 45 62 ± 36 153 ± 46
a50% Eﬀective concentration or compound concentration required to inhibit virus-induced cytopathicity in CEM cell cultures by 50%.
bMutant HIV-1 strains containing a variety of glycan deletions in gp120 as shown in Table 1.
cData expressed in lM.
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Fig. 2. Eﬀect of 1-deoxymannojirimycin on the antiviral eﬀect of GNA
against mutant drug-resistant HIV-1 strains in CEM cell cultures.
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HHA against HIV-1 increased from 25% to 90% in the pres-
ence of DMJ, and from 50% to 100% upon co-administration
of DMJ with 0.16 lg/ml GNA. At lower HHA and GNA con-
centrations, no pronounced antiviral activity was noticed for
the CBAs, neither in the absence, nor in the presence of
DMJ (Fig. 1).
3.3. Antiviral eﬀect of CBAs in combination with DMJ against
mutant HIV-1 strains in CEM cell cultures
Three diﬀerent HIV-1 strains that were shown to contain sev-
eral N-glycan deletions in their gp120 envelope (Table 1) were
exposed to GNA and HHA in the presence of a variety of
DMJ concentrations. When 50, 20 and 8 lM DMJ was com-
bined with GNA (Fig. 2A–C), DMJ acted synergistically in
combination with these CBAs. For example, 4 and 20 lg/ml
GNA that showed poor, if any, antiviral eﬃcacy against HIV-
1/GNA-500(CS) (Fig. 2, panel A) and HIV-1/HHA-500(CS)
(Fig. 2, panel B) became 100% protective against the virus-in-duced cytopathic eﬀect in the presence of 50 lM DMJ, and
40–100% protective in the presence of 20 lM DMJ. Such a
synergistic eﬀect was also seen for DMJ against HIV-1/HHA-
500(SN) when GNA was administered at the higher concentra-
tion range (20–500 lM) (Fig. 2, panel C). A similar synergistic
activity of DMJ was noted against the mutant virus strains
when combined with HHA (Fig. 3, panels A, B and C).
Surprisingly, when the lower GNA and HHA concentra-
tions (0.032–0.8 lM) were combined with DMJ, rather an
antagonistic activity was observed. This phenomenon was con-
sistently seen for both HHA and GNA, in the presence of the
diﬀerent DMJ concentrations (Figs. 2 and 3).
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Fig. 3. Eﬀect of 1-deoxymannojirimycin on the antiviral eﬀect of HHA
against mutant drug-resistant HIV-1 strains in CEM cell cultures.
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combinations in CEM cell cultures
Neither the CBAs (500 lM) nor DMJ (250 lM) proved
inhibitory against CEM cell proliferation whether adminis-
tered to the cell cultures as single drugs or combined (data
not shown). The drug combinations also had no inhibitory ef-
fect on cell metabolism since radiolabeled thymidine, uridine
and leucine incorporation into CEM cell DNA, RNA or pro-
teins was not measurably aﬀected.4. Discussion
The glycosylation inhibitor DMJ targets the ER and Golgi
a(1,2)-mannosidase I that trims the a1,2-mannose(s) from the
Man9(GlcNAc)2 glycan after the ER a-glucosidases I and II
have removed the three terminal glucose units from the N-gly-
can Glc3Man9(GlcNAc)2 block [7,8]. As a result, the amount of
high-mannose type glycan structures on the glycoprotein mark-
edly increases in the presence of DMJ since further trimming/
processing of the high-mannose glycans to hybrid- or com-
plex-type glycans has been largely prevented by the DMJ-med-
iated blockade of the a1,2-mannosidases I. Since the CBAs
GNA and HHA are known to speciﬁcally bind to a(1,3)-and/or a(1,6)-mannose oligomer structures [23], it could be rea-
soned that a higher amount of high-mannose type glycans on
gp120 may allow these CBAs to concomittantly bind to a high-
er amount of glycans on the HIV-1 envelope. Consequently,
they may exert a more pronounced antiviral activity in DMJ-
treated virus-infected cells. We observed indeed a potentiation
of the anti-HIV-1 activity of HHA and GNA in the presence of
DMJ concentrations that exerted themselves no antiviral activ-
ity when used as a single drug. Thus, concomittant administra-
tion of glycosylation inhibitors (such as DMJ) and CBAs in
HIV-1-infected cell cultures may further potentiate the antiviral
activity of the mannose-speciﬁc CBAs.
Interestingly, whereas wild-type virus infection and replica-
tion eﬃciently proceed in the presence of high (i.e. 250 and
100 lM) DMJ concentrations (EC50 > 500 lM), the mutant
HIV-1 strains that contain multiple deletions of N-glycans in
gp120 gained sensitivity to the inhibitory activity of the a1,2-
mannosidase I inhibitorDMJ in theCEMcell cultures.Whereas
DMJ was not eﬀective at all at 500 lMagainst parent wild-type
virus it could indeed inhibit mutant virus infection at an EC50
that ranged between 90 and 150 lM, that is at an at least more
than 5–10-fold lower DMJ concentration. These mutant virus
strains showed 7 or 8 glycan deletions at putative N-glycosyla-
tion sites in gp120 [22], and the deletions preferentially occurred
at high-mannose type glycan sites (Table 1). Such glycan dele-
tions in the mutant HIV-1 strains resulted in a marked pheno-
typic resistance to the HHA and GNA CBAs. It could be
assumed that DMJ converts at least part of the remaining gly-
cans of the mutant gp120 into high-mannose-type glycan struc-
tures, making them more vulnerable to interaction with the
CBAs. Consequently, an increased antiviral activity would then
be expected upon co-administration with DMJ, a phenomenon
that we indeed observed to occur in the HIV-infected cell cul-
tures. Interestingly, a similar phenomenon has been observed
to occur when Pradimicin A, a high mannose-type glycan-bind-
ing antibiotic, was exposed to mammalian U937 cells that had
been pretreated with DMJ [24]. Under these experimental con-
ditions, the cells express high levels of high mannose-type oligo-
saccharides and become sensitive to PRM-A (resulting in
apoptosis induction). No such apoptosis induction was ob-
served in PRM-A-exposed cell cultures that were not pretreated
with DMJ [24,25]. Thus, the combined use of CBAs and the
a1,2-mannosidase-inhibitor DMJ enabled partial restoration
of the phenotypic sensitivity of themutantHIV-1 strains against
the CBAs. Our results argue for combined administration of
CBAs and DMJ to wild-type virus, because phenotypic resis-
tance development may be expected to slow down when DMJ
is present during CBA treatment of HIV-1. The slight but con-
sistently observed antagonistic activity that has been observed
for DMJ when combined with the lowest CBA concentrations
is rather puzzling and the molecular basis of this phenomenon
is yet unclear.
There is, in general, a concern for the therapeutic application
of inhibitors that target cellular enzymes such as the a1,2-man-
nosidase I inhibitor DMJ. Indeed, inhibition of cellular glyco-
sylation enzymes in virus-infected cells may not only
compromise proper viral glycopeptide formation, but may also
have deleterious eﬀects on glycoproteins of non-infected cells.
However, therapy with drugs, in casu glycosylation inhibitors,
should not necessary aim to ablate enzyme activity but should
rather be used to modulate enzyme activities involved in glyco-
sylation [26]. Since the envelope gp120 glycoprotein of HIV is
2064 J. Balzarini / FEBS Letters 581 (2007) 2060–2064among the highest glycosylated glycoproteins currently known
and has a high (functional) requirement of high-mannose type
glycans, it may be assumed that a moderate attenuation of
a1,2-mannosidase I activity may have a more pronounced
deleterious impact on the synthesis of the viral envelope glyco-
protein than on the cellular glycoproteins, allowing for a cer-
tain degree of selectivity of such inhibitors. Proper in vivo
experiments should reveal the therapeutic eﬃcacy and feasibil-
ity of such drugs.
In conclusion, the a(1,2)-mannosidase I inhibitor DMJ was
found to potentiate the inhibitory activity of CBAs against
wild-type HIV-1. Administration of DMJ to cell cultures
infected with mutant HIV-1 strains that contain N-glycan dele-
tions in the gp120 envelope render the mutant virus susceptible
to the inhibitory activity of DMJ. Moreover, DMJ can par-
tially reverse the phenotypic resistance of CBAs to the mutant
virus strains. These three phenomena may argue for further
investigation of glycosidase inhibitors such as, but not limited
to, DMJ to be used in combination with CBAs with the aim to
further potentiate the antiviral activity of the CBAs and to de-
lay resistance development that may develop under CBA drug
pressure.
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